share_log

iBio Inc | S-3: Registration statement for specified transactions by certain issuers

iBio Inc | S-3: Registration statement for specified transactions by certain issuers

iBio Inc | S-3:特定交易注册声明
美股sec公告 ·  04/16 16:16
Moomoo AI 已提取核心信息
iBio Inc, a Delaware-based biotechnology company, filed a Form S-3 registration statement with the Securities and Exchange Commission (SEC) on April 16, 2024. The filing pertains to the resale of up to 10,574,556 shares of common stock by selling stockholders, which includes shares acquired in a private placement transaction that closed on April 1, 2024. The private placement involved the sale of 2,701,315 outstanding shares of common stock, 2,585,963 shares issuable upon the exercise of pre-funded warrants, and 5,287,278 shares issuable upon the exercise of outstanding warrants, collectively known as the 'Selling Stockholders'. The registration statement is part of iBio's contractual obligations to facilitate the resale of these shares by the Selling Stockholders. iBio will not offer any shares under this prospectus and will not...Show More
iBio Inc, a Delaware-based biotechnology company, filed a Form S-3 registration statement with the Securities and Exchange Commission (SEC) on April 16, 2024. The filing pertains to the resale of up to 10,574,556 shares of common stock by selling stockholders, which includes shares acquired in a private placement transaction that closed on April 1, 2024. The private placement involved the sale of 2,701,315 outstanding shares of common stock, 2,585,963 shares issuable upon the exercise of pre-funded warrants, and 5,287,278 shares issuable upon the exercise of outstanding warrants, collectively known as the 'Selling Stockholders'. The registration statement is part of iBio's contractual obligations to facilitate the resale of these shares by the Selling Stockholders. iBio will not offer any shares under this prospectus and will not receive any proceeds from the sale of shares by the Selling Stockholders, except for potential proceeds from the cash exercise of the pre-funded and outstanding warrants. The Selling Stockholders may sell their shares through public or private transactions at prevailing market prices or at negotiated prices. The registration statement also includes information about the Selling Stockholders, the plan of distribution, and legal matters concerning the offering.
总部位于特拉华州的生物技术公司iBio Inc于2024年4月16日向美国证券交易委员会(SEC)提交了S-3表格的注册声明。该文件涉及通过出售股东转售多达10,574,556股普通股,其中包括在2024年4月1日结束的私募交易中收购的股票。此次私募涉及出售2,701,315股已发行普通股,通过行使预先筹资认股权证可发行的2,585,963股股票,以及行使未偿认股权证时可发行的5,287,278股股票,统称为 “卖出股东”。注册声明是iBio合同义务的一部分,旨在促进出售股东转售这些股票。iBio不会根据本招股说明书发行任何股票,也不会从出售股东出售股票中获得任何收益,但预先注资和未偿认股权证的现金行使的潜在收益除外。卖出股东可以通过公开或私人交易以现行市场价格或协议价格出售其股票。注册声明还包括有关出售股东、分配计划以及与发行有关的法律事务的信息。
总部位于特拉华州的生物技术公司iBio Inc于2024年4月16日向美国证券交易委员会(SEC)提交了S-3表格的注册声明。该文件涉及通过出售股东转售多达10,574,556股普通股,其中包括在2024年4月1日结束的私募交易中收购的股票。此次私募涉及出售2,701,315股已发行普通股,通过行使预先筹资认股权证可发行的2,585,963股股票,以及行使未偿认股权证时可发行的5,287,278股股票,统称为 “卖出股东”。注册声明是iBio合同义务的一部分,旨在促进出售股东转售这些股票。iBio不会根据本招股说明书发行任何股票,也不会从出售股东出售股票中获得任何收益,但预先注资和未偿认股权证的现金行使的潜在收益除外。卖出股东可以通过公开或私人交易以现行市场价格或协议价格出售其股票。注册声明还包括有关出售股东、分配计划以及与发行有关的法律事务的信息。
声明:本内容仅用作提供资讯及教育之目的,不构成对任何特定投资或投资策略的推荐或认可。 更多信息